Clovis Oncology Overview
Valuation check: CLVS's ROE is 60.28%, above the Healthcare sector average of 29.33%.
Get informed when a big investor buys or sells
+ Follow60.28%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for CLVS is 60.28%. That is above the Healthcare sector average of 29.33%. Investors often review this figure alongside Clovis Oncology's historical trend and sector peers before judging valuation or financial health.
Against Healthcare companies, CLVS currently prints 60.28% for ROE, while the sector average sits near 29.33%. That is roughly 105.5% above the sector mean. Large gaps often invite a closer look at Clovis Oncology's growth, margins, and balance sheet.
Return on Equity shows how effectively Clovis Oncology converts resources into returns. At 60.28%, CLVS may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting CLVS's ROE (60.28%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack Clovis Oncology's ROE against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.
